Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.

The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.

The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.

The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.

The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.

Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.

The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.